Schmidt P J Investment Management Inc. Sells 236 Shares of Johnson & Johnson $JNJ

Schmidt P J Investment Management Inc. lessened its stake in Johnson & Johnson (NYSE:JNJ) by 1.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,659 shares of the company’s stock after selling 236 shares during the period. Schmidt P J Investment Management Inc.’s holdings in Johnson & Johnson were worth $2,392,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $47,000. 1248 Management LLC purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson during the 1st quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Down 1.1%

Shares of JNJ stock opened at $190.38 on Monday. The stock has a market cap of $458.69 billion, a P/E ratio of 18.38, a PEG ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The company’s fifty day simple moving average is $182.26 and its two-hundred day simple moving average is $166.37.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s payout ratio is presently 50.19%.

Analysts Set New Price Targets

JNJ has been the topic of several analyst reports. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Bank of America lifted their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the company a “neutral” rating in a research note on Wednesday, October 15th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday. Finally, Raymond James Financial lifted their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.